| Net income | -6.48M |
| Decrease in accrued investment income | |
| Depreciation and amortization | |
| Amortization of intangible assets | |
| Change in value / loss on value of UBS option to put securities | |
| Auction rate securities mark to market, trading gain | |
| Provision for doubtful accounts | 223K |
| Excess and obsolete inventory | |
| Deferred income taxes | |
| Stock-based compensation | 3.48M |
| Unrealized (gain)/loss on foreign exchange | |
| Accounts receivable | 12.95M |
| Inventories | -2.41M |
| Prepaid expenses and other assets | 1.56M |
| Accounts payable | -3.15M |
| Accrued compensation and benefits | -7.32M |
| Restructuring liabilities | |
| Accrued warranty | |
| Deferred revenue, net | |
| Deferred distributors revenue, net of cost of sales to distributors | |
| Other accrued liabilities | |
| Other long-term liabilities | -842K |
| Net cash (used in) provided by operating activities | 9.57M |
| Capital expenditures | -1.64M |
| Purchases of investments | |
| Proceeds from maturities of investments and marketable securities | |
| Proceeds from sales of investments and marketable securities | |
| Net cash used in investing activities | -1.64M |
| Proceeds from issuance of common stock | 3.42M |
| Net cash provided by financing activities | 166K |
| Foreign currency effect on cash | 38K |
| Net decrease in cash and cash equivalents | 8.14M |
| Cash and cash equivalents at beginning of period | 94.12M |
| Cash and cash equivalents at end of period | 102.27M |